Sarepta Therapeutics, Inc. (SRPT) Revenue History
Annual and quarterly revenue from 1995 to present
SRPT Revenue Over Time (1995–2025)
SRPT Revenue Growth History
19 of 30 years with positive growth- FY1995 revenue growth
- N/A
- FY1996 revenue growth
- +0.0%
- FY1997 revenue growth
- +0.0%
- FY1998 revenue growth
- +100.0%
- FY1999 revenue growth
- -50.0%
- FY2000 revenue growth
- +1197.3%
- FY2001 revenue growth
- -45.6%
- FY2002 revenue growth
- +18.5%
- FY2003 revenue growth
- +15.9%
- FY2004 revenue growth
- -55.6%
- FY2005 revenue growth
- +1011.3%
- FY2006 revenue growth
- -97.6%
- FY2007 revenue growth
- +9428.2%
- FY2008 revenue growth
- +93.5%
- FY2009 revenue growth
- -17.3%
- FY2010 revenue growth
- +67.3%
- FY2011 revenue growth
- +59.7%
- FY2012 revenue growth
- -20.6%
- FY2013 revenue growth
- -61.9%
- FY2014 revenue growth
- -31.4%
- FY2015 revenue growth
- -87.2%
- FY2016 revenue growth
- +332.6%
- FY2017 revenue growth
- +2751.6%
- FY2018 revenue growth
- +94.7%
- FY2019 revenue growth
- +26.5%
- FY2020 revenue growth
- +41.8%
- FY2021 revenue growth
- +30.0%
- FY2022 revenue growth
- +32.9%
- FY2023 revenue growth
- +33.3%
- FY2024 revenue growth
- +53.0%
- FY2025 revenue growth
- +15.6%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $730.8M | -1.9% |
| Q4 2025 | $442.9M | -32.7% |
| Q3 2025 | $399.4M | -14.5% |
| Q2 2025 | $611.1M | +68.4% |
| Q1 2025 | $744.9M | +80.2% |
| Q4 2024 | $658.4M | +65.9% |
| Q3 2024 | $467.2M | +40.8% |
| Q2 2024 | $362.9M | +38.9% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown
SRPT's revenue distribution by segment and geography
By Geography
SRPT Revenue Analysis (1995–2025)
Current Revenue & Growth
As of June 22, 2026, Sarepta Therapeutics, Inc. (SRPT) generated trailing twelve-month (TTM) revenue of $2.18 billion, reflecting slight decline in growth of -1.9% year-over-year. The most recent quarter (Q1 2026) recorded $730.8 million in revenue, up 65.0% sequentially.
Historical Growth Trajectory
SRPT's 5-year compound annual growth rate (CAGR) stands at +32.4%, indicating outstanding long-term growth trajectory. The 3-year CAGR of +33.1% exceeds the 5-year average, indicating an acceleration in the most recent period. Sarepta Therapeutics, Inc.'s highest annual revenue of $2.20 billion was recorded in 2025, an all-time high.
Peer Comparison
Compared to Healthcare sector peers — including BMRN (+9.9% YoY), ALNY (+82.6% YoY), and RARE (+13.3% YoY) — SRPT has underperformed the peer group in revenue growth. Compare SRPT vs BMRN →
SRPT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SRPTCurrent | $2.2B | -1.9% | +32.4% | -29.9% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% | |
 ALNY | $3.7B | +82.6% | +49.8% | 13.5% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% |
SRPT Historical Revenue Data (1995–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.20B | +15.6% | $1.32B | 59.9% | $-657,772,000 | -29.9% |
| 2024 | $1.90B | +53.0% | $1.58B | 83.2% | $218.1M | 11.5% |
| 2023 | $1.24B | +33.3% | $1.09B | 87.9% | $-267,824,000 | -21.5% |
| 2022 | $933.0M | +32.9% | $793.0M | 85.0% | $-536,201,000 | -57.5% |
| 2021 | $701.9M | +30.0% | $604.8M | 86.2% | $-459,710,000 | -65.5% |
| 2020 | $540.1M | +41.8% | $476.7M | 88.3% | $-564,163,000 | -104.5% |
| 2019 | $380.8M | +26.5% | $324.2M | 85.1% | $-705,563,000 | -185.3% |
| 2018 | $301.0M | +94.7% | $266.8M | 88.6% | $-343,628,000 | -114.1% |
| 2017 | $154.6M | +2751.6% | $147.2M | 95.2% | $-171,638,000 | -111.0% |
| 2016 | $5.4M | +332.6% | $5.3M | 97.6% | $-266,730,000 | -4920.3% |
| 2015 | $1.3M | -87.2% | $-144,941,000 | -11567.5% | $-220,184,000 | -17572.5% |
| 2014 | $9.8M | -31.4% | $-84,346,000 | -864.5% | $-133,789,000 | -1371.2% |
| 2013 | $14.2M | -61.9% | $-76,065,000 | -535.0% | $-90,284,000 | -635.0% |
| 2012 | $37.3M | -20.6% | $-14,604,000 | -39.1% | $-29,703,000 | -79.6% |
| 2011 | $47.0M | +59.7% | $11.1M | 23.5% | $-35,927,000 | -76.5% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
31+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
SRPT — Frequently Asked Questions
Quick answers to the most common questions about buying SRPT stock.
Is SRPT's revenue growth accelerating or slowing?
SRPT revenue growth is slowing. TTM revenue is $2.2B, up -1.9% year-over-year — below the 5-year CAGR of +32.4%. The deceleration suggests maturing end-markets or increased competition.
What is SRPT's revenue history from 1995 to 2026?
Sarepta Therapeutics, Inc. (SRPT) revenue history spans 1995 to 2026. TTM revenue as of 2026 is $2.2B, growing at -1.9% YoY. The 5-year CAGR is +32.4%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is SRPT's long-term revenue growth rate (CAGR)?
Sarepta Therapeutics, Inc.'s 5-year revenue CAGR of +32.4% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -1.9% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for SRPT.
Why does SRPT's quarterly revenue fluctuate?
SRPT quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Sarepta Therapeutics, Inc.'s revenue data from 1995 to 2026 shows full historical quarterly detail on this page.
How is SRPT's revenue distributed by segment?
SRPT reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does SRPT's revenue compare to industry peers?
Sarepta Therapeutics, Inc. (SRPT) with TTM revenue of $2.2B and -1.9% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.